Spontaneous relief of vitreomacular traction and regression of neovascularization in eales disease after intravitreal injection of bevacizumab.
OBJECTIVE
To report the use and sequelae of intravitreal injection of bevacizumab (Avastin; Roche) in Eales disease with persistent active neovascularization and vitreomacular traction.


METHODS
Intravitreal injection of bevacizumab was used to treat Eales disease with a persistent large neovascular frond, vitreous hemorrhage, and vitreomacular traction.


RESULTS
After the injection, there was spontaneous relief of the vitreomacular traction and improvement in visual acuity. Rapid regression of the neovascular frond resulted in a traction retinal break, which was successfully managed with barrage laser photocoagulation.


CONCLUSIONS
Intravitreal injection of bevacizumab seems to be a good option in managing persistent neovascularization in Eales disease. These patients need regular follow-up to recognize the complications that may arise due to the rapid regression of neovascularization.
From Ranjini Eye Care, Cochin, India.
Biju
B
Raju
Narayanan Sivadasa D
NS
Raju
Anju S
AS
Raju
Santha P
SP
Rajamma